Trials / Completed
CompletedNCT00327418
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A Double Blind Placebo Controlled Study of Atorvastatin as Prevention of CHD in High Risk Patients With Non-Insulin Dependent Diabetes Mellitus (Collaborative Atorvastatin Study - CARDS)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,800 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy, microalbuminuria, macroalbuminuria, or who currently smoke, but who do not have established corornary heart disease or other macrovascular disease.
Conditions
- Major Coronary Event
- Cerebrovascular Accident
- Coronary Artery Bypass Graft
- Angina, Unstable
- Revascularization
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin |
Timeline
- Start date
- 1997-01-01
- Completion
- 2004-02-01
- First posted
- 2006-05-18
- Last updated
- 2007-05-10
Locations
135 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00327418. Inclusion in this directory is not an endorsement.